Last reviewed · How we verify
RYSTIGGO (ROZANOLIXIZUMAB-NOLI)
RYSTIGGO (generic name: ROZANOLIXIZUMAB-NOLI) is a Neonatal Fc Receptor Blocker [EPC] drug developed by UCB INC. It is currently FDA-approved for Generalized myasthenia gravis.
Rozanolixizumab, also known as RYSTIGGO, is an antibody that inhibits the IgG receptor FcRn large subunit p51. It is being studied in clinical trials for the treatment of generalized myasthenia gravis.
At a glance
| Generic name | ROZANOLIXIZUMAB-NOLI |
|---|---|
| Sponsor | UCB INC |
| Drug class | Neonatal Fc Receptor Blocker [EPC] |
| Target | IgG receptor FcRn large subunit p51 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Generalized myasthenia gravis
Common side effects
- Infections
- Headache
- Diarrhea
- Pyrexia
- Hypersensitivity reactions
- Nausea
- Upper respiratory tract infections
- COVID-19
- Urinary tract infections
- Herpes simplex
Serious adverse events
- Serious infections
- Pneumonia (fatal)
- Aseptic meningitis
- Severe headache
- Herpes zoster
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RYSTIGGO CI brief — competitive landscape report
- RYSTIGGO updates RSS · CI watch RSS
- UCB INC portfolio CI
Frequently asked questions about RYSTIGGO
What is RYSTIGGO?
RYSTIGGO (ROZANOLIXIZUMAB-NOLI) is a Neonatal Fc Receptor Blocker [EPC] drug developed by UCB INC, indicated for Generalized myasthenia gravis.
What is RYSTIGGO used for?
RYSTIGGO is indicated for Generalized myasthenia gravis.
Who makes RYSTIGGO?
RYSTIGGO is developed and marketed by UCB INC (see full UCB INC pipeline at /company/ucb).
What is the generic name of RYSTIGGO?
ROZANOLIXIZUMAB-NOLI is the generic (nonproprietary) name of RYSTIGGO.
What drug class is RYSTIGGO in?
RYSTIGGO belongs to the Neonatal Fc Receptor Blocker [EPC] class. See all Neonatal Fc Receptor Blocker [EPC] drugs at /class/neonatal-fc-receptor-blocker-epc.
What development phase is RYSTIGGO in?
RYSTIGGO is FDA-approved (marketed).
What are the side effects of RYSTIGGO?
Common side effects of RYSTIGGO include Infections, Headache, Diarrhea, Pyrexia, Hypersensitivity reactions, Nausea. Serious adverse events: Serious infections, Pneumonia (fatal), Aseptic meningitis, Severe headache.
What does RYSTIGGO target?
RYSTIGGO targets IgG receptor FcRn large subunit p51 and is a Neonatal Fc Receptor Blocker [EPC].
Related
- Drug class: All Neonatal Fc Receptor Blocker [EPC] drugs
- Target: All drugs targeting IgG receptor FcRn large subunit p51
- Manufacturer: UCB INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Generalized myasthenia gravis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing